Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 2 (February)

1. Tumor immunobiological differences in prostate cancer between African-American and European-American men.
   Cancer Res, 68(3): 927-36. [Abstract] [Full-text]
2. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
   Cancer Res, 68(3): 861-9. [Abstract] [Full-text]
3. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer.
   Cancer Res, 68(3): 731-9. [Abstract] [Full-text]
4. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
   Cancer Res, 68(3): 645-9. [Abstract] [Full-text]
5. Evidence that senescent human prostate epithelial cells enhance tumorigenicity: cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT.
   Int J Cancer, 122(7): 1483-95. [Abstract] [Full-text]
6. Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts.
   Int J Cancer, 122(7): 1585-91. [Abstract] [Full-text]
7. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival.
   Int J Cancer, 122(7): 1521-9. [Abstract] [Full-text]
8. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.
   J Natl Cancer Inst, 100(3): 170-83. [Abstract] [Full-text]
9. Plasma membrane expression of GnRH receptors: regulation by antagonists in breast, prostate, and gonadotrope cell lines.
   J Endocrinol, 196(2): 353-67. [Abstract] [Full-text]
10. Primary mucosa-associated lymphoid tissue lymphoma of the prostate: tumor relapse 7 years after local therapy.
    Pathol Int, 58(3): 191-5. [Abstract] [Full-text]
11. Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.
    Biochem J, 410(2): 245-53. [Abstract] [Full-text]
12. Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram.
    BJU Int, 101(5): 541-6. [Abstract] [Full-text]
13. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.
    BJU Int, 101(5): 547-55. [Abstract] [Full-text]
14. A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer.
    BJU Int, 101(5): 556-60. [Abstract] [Full-text]
15. The effect of prostate weight on the outcomes of laparoscopic radical prostatectomy.
    BJU Int, 101(5): 589-93. [Abstract] [Full-text]
16. Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo.
    Cancer Lett, 261(1): 74-83. [Abstract] [Full-text]
17. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 70(3): 744-51. [Abstract] [Full-text]
18. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy.
    Int J Radiat Oncol Biol Phys, 70(3): 752-9. [Abstract] [Full-text]
19. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    J Clin Oncol, 26(6): 842-7. [Abstract] [Full-text]
20. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
    J Clin Oncol, 26(6): 835-41. [Abstract] [Full-text]
21. TREK-1 is a novel molecular target in prostate cancer.
    Cancer Res, 68(4): 1197-203. [Abstract] [Full-text]
22. Acetyl-keto-beta-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells.
    Cancer Res, 68(4): 1180-6. [Abstract] [Full-text]
23. Androgen receptor and invasion in prostate cancer.
    Cancer Res, 68(4): 1128-35. [Abstract] [Full-text]
24. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction.
    Cancer Res, 68(4): 1092-9. [Abstract] [Full-text]
25. Prostate-specific antigen screening and mortality from prostate cancer.
    J Gen Intern Med, 23(3): 248-53. [Abstract] [Full-text]
26. Prevalence, severity, and chronicity of pain and general health-related quality of life in patients with localized prostate cancer.
    Eur J Pain, 12(3): 339-50. [Abstract] [Full-text]
27. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.
    Proc Natl Acad Sci U S A, 105(7): 2521-6. [Abstract] [Full-text]
28. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
    BJU Int, 101(6): 691-7. [Abstract] [Full-text]
29. The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer.
    BJU Int, 101(6): 685-90. [Abstract] [Full-text]
30. Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumour-stroma interactions.
    BJU Int, 101(6): 765-74. [Abstract] [Full-text]
31. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
    BJU Int, 101(6): 675-83. [Abstract] [Full-text]
32. Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy.
    Jpn J Clin Oncol, 38(2): 129-33. [Abstract] [Full-text]
33. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer.
    Jpn J Clin Oncol, 38(2): 122-8. [Abstract] [Full-text]
34. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Cancer, 112(3): 521-6. [Abstract] [Full-text]
35. The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents.
    J Pharmacol Exp Ther, 324(3): 1181-7. [Abstract] [Full-text]
36. Loss of the eukaryotic initiation factor 3f in pancreatic cancer.
    Mol Carcinog, 47(3): 235-44. [Abstract] [Full-text]
37. Loss of mir-146a function in hormone-refractory prostate cancer.
    RNA, 14(3): 417-24. [Abstract] [Full-text]
38. BK virus as a cofactor in the etiology of prostate cancer in its early stages.
    J Virol, 82(6): 2705-14. [Abstract] [Full-text]
39. Cumulative association of five genetic variants with prostate cancer.
    N Engl J Med, 358(9): 910-9. [Abstract] [Full-text]
40. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.
    Nat Genet, 40(3): 281-3. [Abstract] [Full-text]
41. Multiple newly identified loci associated with prostate cancer susceptibility.
    Nat Genet, 40(3): 316-21. [Abstract] [Full-text]
42. Multiple loci identified in a genome-wide association study of prostate cancer.
    Nat Genet, 40(3): 310-5. [Abstract] [Full-text]
43. The effect of comorbidities and socioeconomic status on sexual and urinary function in men undergoing prostate cancer screening.
    J Sex Med, 5(3): 668-76. [Abstract] [Full-text]
44. Management of metastatic prostate cancer: the crucial role of geriatric assessment.
    BJU Int, 101: 23-9. [Abstract] [Full-text]
45. Management of localized prostate cancer in senior adults: the crucial role of comorbidity.
    BJU Int, 101: 16-22. [Abstract] [Full-text]
46. Chemotherapy in hormone-refractory prostate cancer.
    BJU Int, 101: 11-5. [Abstract] [Full-text]
47. Localized prostate cancer: can we better define who is at risk of unfavourable outcome?
    BJU Int, 101: 5-10. [Abstract] [Full-text]
48. How to implement the multidisciplinary approach in prostate cancer management: the Belgian model.
    BJU Int, 101: 2-4. [Abstract] [Full-text]
49. MR imaging of prostate after treatment with high-intensity focused ultrasound.
    Radiology, 246(3): 833-44. [Abstract] [Full-text]
50. Downregulation of thymosin beta4 expression by androgen in prostate cancer LNCaP cells.
    J Androl, 29(2): 207-12. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.